NCT03415399View on ClinicalTrials.gov

Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

September 9, 2017

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Lymphoma, B-Cell
Interventions
BIOLOGICAL

ET190L1 ARTEMIS™ T cells

Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) ARTEMIS™ expression construct

Trial Locations (1)

100015

Peking University Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
collaborator

Peking University

OTHER

lead

Eureka Therapeutics Inc.

INDUSTRY